<DOC>
	<DOCNO>NCT02069704</DOCNO>
	<brief_summary>This multicenter , open label , randomize bioequivalence study BEVZ92 ( bevacizumab biosimilar ) Avastin® 2 parallel arm compare PK profile BEVZ92 Avastin® combination FOLFOX ( ) FOLFIRI chemotherapy . FOLFOX ( ) FOLFIRI choose per investigator criterion base hospital standard care .</brief_summary>
	<brief_title>Bioequivalence Study Bevacizumab Biosimilar ( BEVZ92 ) Versus Bevacizumab ( AVASTIN® ) First-line Treatment mCRC Patients</brief_title>
	<detailed_description>Planned enrolment duration : 12 month . Pre-treatment period ( included enrolment period ) : 1 month . Treatment period : Patients continue treatment disease progression unacceptable toxicity , withdrawal consent .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Patient must prior chemotherapy advanced metastatic disease . Patients could receive adjuvant chemotherapy adjuvant chemoradiotherapy . 2 . Patient mCRC biochemotherapy indicate . 3 . Patients must least one measurable nonirradiated site disease accord RECIST ( version 1.1 ) criterion . If patient previous irradiation marker lesion ( ) , must evidence progression since radiation . 4 . Minimum 4 week since major surgery , completion radiation , completion prior systemic anticancer therapy 5 . ECOG performance status ≤ 2 . 6 . Adequate bone marrow function 7 . Adequate liver function define within specific parameter 8 . Adequate renal function define within specific parameter 9 . Adequate coagulation parameter define within specific parameter 10 . Negative pregnancy test female childbearing potential . 11 . Use effective form contraception study ( subject childbearing potential partner ) . 12 . Life expectation ≥ 3 month 1 . Prior treatment advance metastatic colorectal cancer . 2 . Prior treatment antiangiogenesis agent , either neoadjuvant adjuvant setting . 3 . Concurrent use investigational antineoplastic agent ( include 4 week prior enrolment ) . 4 . History malignancy unless malignancy complete remission patient therapy malignancy least 5 year . 5 . Chronic treatment systemic steroid immunosuppressive agent ; topical inhale corticosteroid allow . 6 . Scheduled immunization attenuate live vaccine study period within 1 week prior study entry . 7 . Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastasis . 8 . Patients active bleed history bleed diathesis oral antivitamin K medication ( except low dose coumadin ) within past 6 month prior randomization coagulopathy . 9 . Patients history cerebral vascular accident , transient ischemic attack , subarachnoid haemorrhage within past 6 month prior randomization . 10 . Patients severe and/or uncontrolled medical condition condition could affect participation study 11 . Patients serious nonhealing wound , ulcer , bone fracture , major surgical procedure , significant traumatic injury within 4 week prior randomization 12 . Patients clinical symptom sign gastrointestinal obstruction require parenteral hydration and/or nutrition . 13 . Patients history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month prior randomization . 14 . Patients history hypersensitivity study drug ingredient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>first-line treatment</keyword>
	<keyword>comparability</keyword>
</DOC>